Therefore, 228 june 2013, vol. 71, no 5 © Van Zuiden Communications B.V. All rights reserved. FH patients still have a large residual CVD risk despite the use of statins and there is a medical need for new additional drugs to further lower LCL-C in patients with FH to improve the prognosis of these patients.